Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Charter Communications
CHTR
|
+$601M |
| 2 |
Parker-Hannifin
PH
|
+$576M |
| 3 |
JPMorgan Chase
JPM
|
+$575M |
| 4 |
Goldman Sachs
GS
|
+$452M |
| 5 |
FedEx
FDX
|
+$371M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$733M |
| 2 |
American Tower
AMT
|
+$684M |
| 3 |
Nike
NKE
|
+$601M |
| 4 |
AGN
Allergan plc
AGN
|
+$561M |
| 5 |
McDonald's
MCD
|
+$536M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.7% |
| 2 | Consumer Discretionary | 17.46% |
| 3 | Healthcare | 13.37% |
| 4 | Communication Services | 12.12% |
| 5 | Financials | 11.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ENLC
476
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
| $10.3M | 0.01% |
+540,815
| New | +$9.27M |
|
477
Kosmos Energy
KOS
$1.52B
| $10.2M | 0.01% |
1,448,985
-193,255
| -12% | -$1.1M |
|
|
BECN
478
DELISTED
Beacon Roofing Supply, Inc.
BECN
| $10.1M | 0.01% |
220,301
-258,020
| -54% | -$11.5M |
|
|
MPG
479
DELISTED
Metaldyne Performance Group Inc.
MPG
| $9.98M | 0.01% |
434,939
-78,184
| -15% | -$1.49M |
|
480
Turning Point Brands
TPB
$1.47B
| $9.63M | 0.01% |
786,141
-124,224
| -14% | -$1.65M |
|
481
Chemours
CC
$2.57B
| $9.48M | 0.01% |
429,042
-64,603
| -13% | -$1.33M |
|
482
Norfolk Southern
NSC
$75B
| $9.34M | 0.01% |
86,452
+26,474
| +44% | +$2.67M |
|
|
ENLK
483
DELISTED
EnLink Midstream Partners, LP
ENLK
| $9.06M | 0.01% |
491,717
+299,641
| +156% | +$5.21M |
|
|
GNMX
484
DELISTED
Aevi Genomic Medicine Inc
GNMX
| $8.91M | 0.01% |
1,720,838
+4,988
| +0.3% | +$26.2K |
|
|
AVXS
485
DELISTED
AveXis, Inc. Common Stock
AVXS
| $8.77M | 0.01% |
183,786
+641
| +0.3% | +$34.3K |
|
486
Marcus & Millichap
MMI
$1.18B
| $8.77M | 0.01% |
328,230
+6,229
| +2% | +$162K |
|
487
Energy Transfer Partners
ET
$69.6B
| $8.69M | 0.01% |
449,795
+52,561
| +13% | +$877K |
|
488
BioCryst Pharmaceuticals
BCRX
$2.35B
| $8.58M | 0.01% |
1,355,100
+3,770
| +0.3% | +$19.6K |
|
489
Berkshire Hathaway Class B
BRK.B
$1.1T
| $8.49M | 0.01% |
52,096
+30,691
| +143% | +$4.73M |
|
490
Johnson & Johnson
JNJ
$617B
| $8.48M | 0.01% |
73,632
+45,875
| +165% | +$5.3M |
|
|
PETX
491
DELISTED
Aratana Therapeutics, Inc.
PETX
| $8.23M | 0.01% |
1,146,927
-75,080
| -6% | -$607K |
|
492
Corvus Pharmaceuticals
CRVS
$1.11B
| $8.15M | 0.01% |
570,201
+874
| +0.2% | +$13.3K |
|
|
CWEN.A
493
DELISTED
Clearway Energy Class A
CWEN.A
| $8.07M | 0.01% |
525,694
-626,525
| -54% | -$9.43M |
|
|
ETP
494
DELISTED
Energy Transfer Partners, L.P.
ETP
| $7.39M | 0.01% |
307,692
-207,482
| -40% | -$5.24M |
|
|
DSCI
495
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $7.34M | 0.01% |
1,412,577
+2,909
| +0.2% | +$13.7K |
|
496
Agios Pharmaceuticals
AGIO
$1.95B
| $7.09M | 0.01% |
169,799
+547
| +0.3% | +$28.7K |
|
497
USA Compression Partners
USAC
$3.79B
| $6.97M | 0.01% |
403,048
+35,859
| +10% | +$639K |
|
498
Verizon
VZ
$193B
| $6.93M | 0.01% |
129,903
+71,248
| +121% | +$3.56M |
|
499
PUT
Regeneron Pharmaceuticals
REGN
$77.4B
| $6.5M | 0.01% |
+17,700
| New | +$6.73M |
|
500
Intel
INTC
$460B
| $6.3M | 0.01% |
173,702
+82,722
| +91% | +$2.96M |
|
Similar funds
Jennison Associates's Q4 2016 Portfolio in Review
As of Q4 2016, Jennison Associates held 857 positions worth $89.6B, down 3.4% from $92.8B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Jennison Associates withdrew a net $3.76B in Q4 2016, closing 52 positions and reducing 313 holdings. Its most notable exit was lululemon athletica, an estimated $342M position sold in full.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Jennison Associates opened a new position in Parker-Hannifin worth $606M.
- Jennison Associates's largest Q4 2016 buy was Parker-Hannifin: 4,330,276 shares worth $606M.
- Jennison Associates added most to Charter Communications in Q4 2016, an estimated $601M increase.
- Jennison Associates's biggest Q4 2016 reduction was Biogen, cutting an estimated $733M.
- Jennison Associates fully exited lululemon athletica in Q4 2016, selling an estimated $342M.
- Jennison Associates's ten largest holdings make up 25% of its $89.6B portfolio in Q4 2016.
- Jennison Associates opened 208 new positions and closed 52 in Q4 2016.
- Jennison Associates's portfolio value fell 3.4% quarter-over-quarter to $89.6B.
Based on Jennison Associates's 13F filing for Q4 2016, filed 6 Feb 2017.